Bringing these highly complex molecules from concept to commercialization requires not only specialized technical expertise, but also close integration across development and manufacturing stages.
As the Antibody-Drug Conjugate (ADC) market continues to expand, developers face increasing scientific, operational, and manufacturing complexity across the ADC lifecycle. Bringing these highly complex molecules from concept to commercialization requires not only specialized technical expertise, but also close integration across development and manufacturing stages.
An integrated ADC approach can simplify development pathways, reduce handoffs between vendors, and support more efficient progression from preclinical studies through commercial supply. This webinar will explore the benefits of an end‑to‑end ADC model, including how coordinated development, scalable manufacturing strategies, and lifecycle oversight can help mitigate risk, accelerate timelines, and support consistent product quality.
Drawing on Lonza’s experience supporting ADC programs across multiple stages of development and commercialization, the session will also share practical insights into how integrated capabilities are applied in real-world ADC manufacturing and how they can be leveraged to support long‑term program success.
Most registrants disappear after the session ends. We help you
open the right doors before, during, and after the webinar.
<span>By ticking this box, you consent to receiving communications from Lonza related to this topic and other products or services within their portfolio</span>
